Wockhardt Limited's Board of Directors, at its meeting held on May 4, 2026, identified and designated three individuals as Senior Management Personnel (SMP) of the Company, in compliance with Regulation 30 (read with Part A of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newly designated SMPs are Ms. Annapurna Das, Mr. Om Narayan, and Mr. Sunil Soni, each taking on senior leadership roles across the company's commercial and biotechnology functions.

Senior Management Designations at a Glance

The following table summarises the key details of the three newly designated Senior Management Personnel:

Profile: Ms. Annapurna Das — President, India Business & Emerging Markets (NCE)

Ms. Annapurna Das, aged 52 years, holds a B.Tech (Chemical Engineering) degree from BIT Sindri and an M.B.A. (Marketing) from Madurai Kamraj University. She brings over 26 years of experience across general management, strategy, and commercial operations in India and Asia. Prior to this designation, she served as Vice President and General Manager at Takeda India, where she led the India and Sri Lanka business for a super-specialty portfolio spanning oncology, biologics, gastroenterology, and rare diseases. She also served as Managing Director and Area Head for India and Southeast Asia at Miltenyi Biotec, where she established and scaled cell and gene therapy operations in the region. Additionally, she held senior leadership roles at Sanofi, including non-independent Board member and Head of Asia (Vaccines), as well as strategy and business development roles at MSD, GSK, Pfizer, and Organon.

Profile: Mr. Om Narayan — Senior Vice President, Biotech Research Centre

Mr. Om Narayan, aged 52 years, holds a Master's degree in Biotechnology from Goa University (1995). He brings nearly three decades of diverse experience across R&D, manufacturing, biosimilars, and vaccines. Over the course of his career, he has held senior leadership roles at organisations including Piramal Pharmaceuticals, Kashiv BioSciences, Mylan (Viatris), Biological E Limited, Intas Biopharma, Avesthagen, Serum Institute of India, and Wockhardt Research Center. His contributions span multiple global biosimilar and vaccine approvals as well as facility setups.

Profile: Mr. Sunil Soni — Senior Vice President, Biotechnology

Mr. Sunil Soni, aged 54 years, holds a Master's degree in Bio-Chemical Engineering & Biotechnology from IIT Delhi (1993). He brings nearly three decades of rich experience in projects, manufacturing operations, process development, scale-up, and process improvement initiatives across API and biotech industries. He has held senior leadership roles at Biological E., Serum Institute of India, Concord Biotech Ltd, Gujarat Themis Biosyn Ltd, Wockhardt Ltd., and Lupin Chemicals Ltd, contributing across process operations, equipment design operations, manufacturing operations, production planning & inventory control, and projects & commissioning.

Regulatory Disclosure

The designations have been disclosed in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The information has also been made available on the company's official website at https://www.wockhardt.com . The disclosure was signed by Ms. Rashmi Mamtura, Company Secretary of Wockhardt Limited.

Wockhardt Limited has announced the opening of a special window for re-lodgment of transfer requests for shares held in physical form through a newspaper advertisement published on April 18, 2026. The pharmaceutical company made this disclosure to comply with regulatory requirements under SEBI guidelines.

Regulatory Compliance Details

The announcement was made pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The initiative follows SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated January 30, 2026, which mandated the opening of special windows for physical share transfer re-lodgment.

Stock Exchange Communication

Wockhardt Limited formally communicated this development to both major stock exchanges through reference number WOCK/SEC/SE/2026-27/005 dated April 18, 2026. The communication was addressed to:

Accessibility and Documentation

The company has ensured transparency by making the newspaper advertisement accessible through multiple channels. A copy of the advertisement has been made available on the company's official website at https://www.wockhardt.com/investors/announcements-disclosures/ . This digital availability ensures that shareholders and stakeholders can easily access the information regarding the special window for physical share transfers.

Corporate Authorization

The disclosure was authorized and signed by Rashmi Mamtura, Company Secretary of Wockhardt Limited, with digital signature authentication completed on April 18, 2026, at 18:41:31 +05'30'. This formal authorization demonstrates the company's commitment to proper corporate governance and regulatory compliance in matters related to shareholder services and physical share management.